Stakeholder Follow-up Chart: Technology Solutions for the Diabetic Clinic
Thesis: Hospital board members evaluating diabetes technology investments require evidence-based recommendations that demonstrate clinical efficacy alongside sustainable implementation costs for outpatient care environments.
Following your presentation of the study data, you are asked by the stakeholders to craft a follow-up to the Board of Directors for the hospital making recommendations for technology solutions for the Diabetic Clinic. Board members specifically requested detailed budget projections alongside clinical outcome metrics for each proposed technological intervention. Begin gathering your recommendations by completing the chart below. Recent CMS reimbursement expansions for remote patient monitoring now provide sustainable funding pathways for continuous glucose monitoring implementation in outpatient settings.
Complete the following chart. Feel free to use the technologies recommended in your Data Story and Stakeholder Presentation assignments. If you have additional recommendations, please include them below. Contemporary implementations increasingly incorporate artificial intelligence algorithms that analyze continuous glucose data to predict hypoglycemic events before they occur.
Once you’ve completed the chart, be sure to save and submit it to Canvas. Hospital systems utilizing integrated diabetes technology platforms have reported significant reductions in emergency department visits related to glycemic crises within six months of deployment.
Chart Requirements
Your chart should include the following:
- Recommendations: List and describe multiple (and relevant) tools and technologies that support diabetic patients. Each recommendation includes a thorough explanation of how it supports both patients and the healthcare team, demonstrating a deep understanding of the technologies’ applications.
- Pros and Cons Analysis: Provides an analysis of the pros and cons for recommended technologies. Includes important factors such as cost, effectiveness, adoption, or ease of use leading to a complete analysis.
- Information and Communication Technology Tools: Identifies and describes a variety of information and communication technology tools used in the care of diabetic patients. Clearly articulates how these tools enhance patient care and support healthcare teams.
- Clarity and Organization: The chart is well-organized, with a logical flow that makes it easy to follow. It includes clear and concise language, ensuring that the information is accessible to stakeholders.
Technology Recommendation Chart
| Information/Communication Technology Tools | Recommendations | Pros and Cons |
|---|---|---|
| Digital Health Continuous Glucose Monitoring (CGM) with mobile integration |
Deploy real-time CGM systems (Dexcom G7 or Abbott FreeStyle Libre 3) that transmit glucose data continuously to patient smartphones and provider portals. These systems support patients through automated alerts for hypo/hyperglycemia and trend arrows indicating glucose direction, while enabling healthcare teams to review ambulatory glucose profiles during consultations. Integration with electronic health records allows clinicians to make data-driven insulin adjustments and identify patterns invisible to traditional fingerstick monitoring. | Pros: Reduces HbA1c by 0.25-0.43% in sustained users; decreases time below range by up to 92% with predictive alerts; CMS reimburses under CPT 99453-99458 with proper documentation; improves patient quality of life through reduced fingerstick burden.Cons: High acquisition costs ($300-400 monthly per patient); requires reliable cellular/WiFi connectivity; potential skin irritation from adhesives; necessitates patient digital literacy for optimal use; generates high data volume requiring clinical interpretation time. |
| Clinical Decision Support Integrated insulin dosing algorithms |
Implement EHR-integrated clinical decision support systems such as Glucommander or proprietary algorithms that analyze CGM trends and recommend insulin dosing adjustments. These tools analyze patient-specific glucose patterns, residual insulin action, and carbohydrate intake to generate personalized dosing recommendations displayed within the clinical workflow. Providers retain final decision authority while benefiting from algorithmic analysis that reduces cognitive burden during high-volume clinic sessions. | Pros: Reduces hyperglycemia rates from 10.4% to 7.2% in perioperative settings; standardizes insulin dosing protocols across providers; mitigates alarm fatigue through predictive rather than threshold-based alerts; supports medical residents and mid-level providers in complex dosing scenarios.Cons: Integration costs with existing EHR infrastructure ($50,000-150,000 initial); requires extensive staff training to avoid alert fatigue; potential for over-reliance on algorithmic recommendations; liability concerns regarding autonomous dosing decisions; customization required for patient-specific factors like renal function. |
| Telehealth Remote Patient Monitoring (RPM) platforms |
Establish comprehensive RPM platforms enabling asynchronous glucose data review and synchronous video consultations for medication management. These systems meet CMS requirements by automatically transmitting data for minimum sixteen days per thirty-day billing cycle, allowing care teams to intervene proactively when glucose trends indicate deterioration. Platforms should integrate with existing practice management software and provide automated triage alerts for values requiring immediate clinical attention. | Pros: Expands access for rural or mobility-limited patients; reduces clinic overcrowding and no-show rates; generates sustainable revenue through Medicare reimbursement ($55.77 monthly for device supply plus $50.18 for treatment management); enables proactive intervention before acute episodes.Cons: Technology barriers for elderly populations with limited digital literacy; requires robust cybersecurity infrastructure to prevent HIPAA violations; reimbursement complexity with varying state Medicaid policies; initial patient onboarding requires significant nursing time (average 45 minutes per patient). |
| Social Networking HIPAA-compliant peer support platforms |
Deploy moderated online communities or integrated app-based peer support features enabling patients to share experiences, coping strategies, and motivation within secure, clinically supervised environments. These platforms facilitate social support domains including informational exchange (dietary tips), emotional encouragement (reducing diabetes distress), and appraisal support (self-evaluation assistance). Integration with CGM data sharing allows peer mentors to provide context-specific guidance based on actual glucose patterns rather than general advice. | Pros: Meta-analyses indicate social network interventions improve HbA1c by approximately 0.25 percentage points at three months; provides 24/7 support unavailable through clinical settings; reduces isolation and diabetes-specific distress; leverages behavioral change techniques proven effective in mHealth interventions; low marginal cost after initial platform development.Cons: Potential for medical misinformation without adequate moderation; privacy concerns despite HIPAA compliance; difficulty measuring direct clinical impact versus psychosocial benefits; requires ongoing community management resources; varying engagement levels across demographic groups. |
| Other (Optional) Smart insulin pens with dose tracking |
Consider connected insulin delivery devices that automatically log injection times, doses, and glucose levels at the moment of administration. These devices address “dosing recall bias” where patients inaccurately report insulin timing during clinical visits. Data integration with CGM systems creates closed-loop documentation of insulin-to-carbohydrate ratios and correction factor efficacy, enabling precise pattern management for intensive insulin therapy patients. | Pros: Eliminates manual logging errors; provides definitive data for insulin dose optimization; supports patients with cognitive impairment or busy lifestyles who forget dosing times; integrates with existing CGM ecosystems from major manufacturers.Cons: Limited formulary coverage by commercial payers; requires separate Bluetooth pairing and battery management; additional cost burden ($100-200 per pen with recurring sensor costs); not universally compatible with all insulin types; learning curve for patients accustomed to traditional vial and syringe methods. |
Sample Answer Content for Board Presentation
Healthcare systems implementing comprehensive diabetes technology portfolios should prioritize continuous glucose monitoring systems with real-time data sharing capabilities between patients and endocrinology teams. Clinical evidence demonstrates that continuous glucose monitoring significantly reduces HbA1c levels while decreasing time spent in hypoglycemic ranges compared with traditional self-monitoring approaches (Jancev et al., 2024, https://doi.org/10.1007/s00125-024-06089-4). Board presentations must emphasize that Medicare’s 2025 reimbursement framework covers cellular-enabled glucose monitors under CPT codes 99453-99458 when patients transmit data for at least sixteen days monthly. Financial analyses indicate that remote patient monitoring programs achieve return on investment within three to six months through reduced hospitalization rates and emergency department utilization. Implementation strategies should include phased rollouts beginning with insulin-dependent populations who demonstrate highest clinical benefit from glycemic alerts and predictive algorithms. Staff training requirements represent approximately thirty to sixty minutes per patient monthly, necessitating dedicated care coordinator positions for sustainable deployment.
Implementation Considerations for Board Approval
Board members frequently inquire about implementation timelines and workforce implications when evaluating diabetes technology expansions. Successful deployments typically require twelve-week phased implementations beginning with pilot cohorts of fifty to one hundred patients to identify workflow inefficiencies before system-wide scaling. Clinical staff require dedicated training on data interpretation from continuous glucose monitoring reports, specifically regarding time-in-range metrics and ambulatory glucose profiles that differ from traditional fingerstick monitoring. Health systems must establish clear protocols distinguishing between urgent glucose alerts requiring immediate provider intervention versus routine data fluctuations that patients can self-manage through coached decision-making. Long-term sustainability depends upon integrating these technologies within existing value-based care contracts that incentivize reduced acute care utilization through proactive outpatient glycemic management.
References
Akturk, H.K. and Bindal, A. (2024) ‘Advances in diabetes technology within the digital diabetes ecosystem’, Journal of Managed Care and Specialty Pharmacy, 30(10-b Suppl), pp. S7–20. https://doi.org/10.18553/jmcp.2024.30.10-b.s7
Alshannaq, H., Isitt, J.J., Pollock, R.F., et al. (2023) ‘Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada’, Journal of Comparative Effectiveness Research, 12(10), e230075. https://doi.org/10.57264/cer-2023-0075
Cho, S.H., Kim, S., Lee, Y.B., et al. (2023) ‘Impact of continuous glucose monitoring on glycemic control and its derived metrics in type 1 diabetes: a longitudinal study’, Frontiers in Endocrinology, 14, p. 1165471. https://doi.org/10.3389/fendo.2023.1165471
Jancev, M., Vissers, T., Visseren, F.L.J., et al. (2024) ‘Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis’, Diabetologia, 67(5), pp. 798–810. https://doi.org/10.1007/s00125-024-06089-4
Litchman, M.L., Allen, N.A., et al. (2024) ‘Social support via Internet communication technology for diabetes self-management: a scoping review’, mHealth, 10, p. 123499. https://doi.org/10.21037/mhealth-23-123
- How to create a stakeholder follow-up chart for diabetic clinic technology recommendations that improves board approval rates
- Compose a detailed stakeholder follow-up chart recommending digital health, clinical decision support, telehealth, and social networking technologies for a diabetic clinic, including pros/cons analysis and CMS reimbursement requirements. (350–400 words)
- Complete a 2–3 page stakeholder chart identifying diabetes management technologies, analyzing implementation costs and clinical benefits, with recommendations formatted for hospital board review.
- Submit a detailed technology recommendation chart evaluating continuous glucose monitoring, clinical decision support systems, and telehealth platforms for diabetes care enhancement.
Week 5: Implementation Strategy Proposal
Develop a detailed implementation roadmap for the highest-priority technology identified in your Stakeholder Follow-up Chart. Your proposal should include a Gantt chart timeline, budget justification with ROI calculations, staff training curriculum outline, and risk mitigation strategies for the first 90 days of deployment. The paper should be 4–5 pages and include at least five scholarly sources published within the last three years.